While non-Hodgkin’s lymphoma and melanomas have activating EZH2 mutations58, and overexpression of EZH2 has been reported in solid tumors59, we did not observe these alterations in mesenchymal TNBCs. The gene discussed is EZH2; the disease is melanoma.